SurfSpec is a new framework for lead optimization that improves drug specificity without needing off‑target structures. It works by measuring and reducing the geometric mismatch between a ligand and its target pocket, using the triangle inequality to infer a lower bound on mismatch to off‑target pockets. In tests on the CrossDocked2020 dataset, SurfSpec lowers geometric mismatch and achieves higher empirical specificity while still improving target affinity.
By Minyeong Hwang, Yoorim Gang, Ziseok Lee, Wooyeol Lee, Young Bin Park, Jae-Mun Choi, Kyungsu Kim, Eunho Yang
SpecOpt is a new molecular design task that optimizes the binding specificity of existing drugs by making constrained structural modifications. The method uses an agentic framework that docks a compound against its intended target and known off‑targets, compares residue‑aware atom‑protein contacts, and feeds the differential interactions to a large language model to propose changes. On a benchmark of 915 compounds, SpecOpt increased the target‑off‑target binding gap for 84.8% of cases while preserving drug‑like properties and structural similarity.
By Thao Nguyen, Heng Ji
arXiv:2606. 00555v1 Announce Type: new Abstract: Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting objectives -- binding affinity and druggability -- which single optimization steps rarely improve together.
By Zaifei Yang, Weiyu Chen, Yaqing Wang, James Kwok
arXiv:2608. 11483v1 Announce Type: new Abstract: Hit-to-lead optimization requires iterative design of hit analogs across competing potency, selectivity, physicochemical, pharmacokinetic, safety, and synthetic constraints.
By Kelvin P. Idanwekhai, Enes Kelestemur, Benjamin Strickland, Matthew Hart, Steini Davidsson, Angelos Angelopoulos, Ron Alterovitz, Marcello DeLuca, Alexander Tropsha
PMO-Dock introduces a standardized benchmark for docking‑based molecular optimization, comprising 25 tasks that span hit generation, lead optimization, and a specificity task that rewards strong on‑target binding while penalizing off‑target interactions. The protocol separates model development from final evaluation, using validation tasks for hyperparameter tuning and held‑out test tasks evaluated under a strict oracle budget to mimic realistic drug‑discovery constraints. Four diverse methods—Saturn, GenMol, Genetic‑guided GFlowNet, and ChemLlama—were benchmarked, revealing no single method dominates across all tasks and highlighting limited hyperparameter transferability, which underscores the need for method‑dependent selection strategies.
By Gor Simonyan, Tatevik Abrahamyan, Narek Abelyan, Tigran Fahradyan, Hrant Khachatrian
Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design. Many such models follow the structure-based drug design (SBDD) paradigm, generating molecules to fit a target binding pocket.